undamentalytics Newsletter

Junius Daniel M: insider trades

Director at 2 companies we cover. 6 open-market purchases and 10 sales not made under a pre-set plan, reported from August 5, 2015 to May 14, 2025.

Would copying Junius Daniel M’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 2 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on August 6, 2015 into $51,994 by November 2, 2026, +15.8% a year. The copy held shares only 18% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $16,532, +4.6% a year (the S&P 500 held throughout made $43,657, +14.0% a year). Beta against the index was 0.10. Twelve months after each report, the average purchase was +99.4% against the S&P 500 (median +99.4%), and 100% beat it. Measured from the trade date, the insider’s own timing, the average was +87.5%. After their sales, the shares moved −1.1% against the index over 12 months on average (a negative figure means selling was the right call); 50% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$20.0k$40.0k 201520172019202120232025 $52.0k$43.7k$16.5k
Copying Junius Daniel MS&P 500, same days investedS&P 500, held throughout $10,000 copying Junius Daniel M’s open-market purchases from August 6, 2015, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
+15.8%
S&P 500, same days invested
+4.6% (held throughout +14.0%)
Time in shares
18%
Sharpe ratio (S&P 500)
0.47 (0.70)
Biggest drop (S&P 500)
−41% (−34%)
Market sensitivity (beta)
0.10
Purchases copied
2

Trade by trade

Junius Daniel M: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 2 −9.4% −9.4% 0% 2 — — Not enough years
Purchases, 6 months after the report 2 +50.9% +50.9% 100% 2 — — Not enough years
Purchases, 12 months after the report 2 +99.4% +99.4% 100% 2 — — Not enough years
Purchases, 12 months after the trade 2 +87.5% +87.5% 100% 2 — — Not enough years
Sales, 3 months after the report 10 +8.1% +12.2% 30% 7 2.95 0.025 Some evidence: seller wrong
Sales, 12 months after the report 10 −1.1% −2.4% 50% 7 0.05 0.96 No reliable evidence
Sales, 12 months after the trade 10 −2.0% −4.6% 50% 7 −0.05 0.96 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Idexx Laboratories IDXX —110August 5, 2015May 14, 2025
Crescent Biopharma, Inc. CBIO —50December 21, 2016May 11, 2023

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
May 14, 2025May 13, 2025 IDXX Sale $1,358,698 +17.8%−19.9%−24.3%
May 11, 2023May 10, 2023 CBIO Purchase $46,800 not yetnot yetnot yet
February 17, 2023February 16, 2023 IDXX Sale $1,119,044 −3.6%−9.6%−14.7%
December 7, 2022December 5, 2022 IDXX Sale $1,294,276 +9.9%+6.7%+7.9%
November 18, 2022November 17, 2022 CBIO Purchase $37,400 not yetnot yetnot yet
August 12, 2021August 10, 2021 IDXX Sale $1,632,351 −12.8%−39.4%−36.6%
May 24, 2021May 21, 2021 IDXX Sale $1,348,925 +13.7%−30.2%−26.1%
February 24, 2021February 22, 2021 IDXX Sale $1,022,212 −2.4%−15.2%−22.5%
August 21, 2020August 20, 2020 IDXX Sale $1,424,074 +17.9%+44.1%+44.9%
May 20, 2020May 19, 2020 IDXX Sale $1,182,440 +15.8%+41.3%+36.2%
March 10, 2020March 9, 2020 CBIO Purchase $68,000 not yetnot yetnot yet
August 15, 2019August 13, 2019 CBIO Purchase $31,800 not yetnot yetnot yet
March 2, 2018February 28, 2018 IDXX Sale $565,238 +13.1%+4.9%+10.1%
February 9, 2017February 8, 2017 IDXX Sale $425,250 +11.4%+6.6%+5.4%
December 21, 2016December 20, 2016 CBIO Purchase $30,050 −11.0%+160.7%+137.2%
August 5, 2015August 3, 2015 IDXX Purchase $73,150 −7.9%+38.0%+37.8%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Junius Daniel M traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.